Results of the summarizing process for the arXiv paper: 1801.10193v2

In the field of drug discovery, identifying new drug-target (DT) interactions is crucial. While many computational methods have been proposed to predict DT interactions, most focus on binary classification - determining whether a DT pair interacts or not. However, protein-ligand interactions involve a continuum of binding strength values, known as binding affinity, which remains a challenge to predict accurately. With the increase in available affinity data in DT knowledge-bases, advanced learning techniques such as deep learning architectures can be used to predict binding affinities. This study proposes a deep-learning based model that uses only sequence information of both targets and drugs to predict DT interaction binding affinities. Unlike previous studies that use either 3D structures of protein-ligand complexes or 2D features of compounds for prediction, this work models protein sequences and compound 1D representations with convolutional neural networks (CNNs). The results show that the proposed deep learning-based model using 1D representations of targets and drugs is an effective approach for drug target binding affinity prediction. The authors also compare their model's performance against two state-of-the-art methods: KronRLS algorithm and SimBoost. In one larger benchmark dataset, their model achieved the best Concordance Index (CI) performance by constructing high-level representations of a drug and a target via CNNs. This outperformed both KronRLS algorithm and SimBoost. Overall, this study presents a novel approach for predicting DT interaction binding affinities using deep learning architecture with only sequence information. The results demonstrate its effectiveness compared to other state-of-the-art methods and highlight its potential application in drug discovery research.

• - Identifying new drug-target interactions is crucial in drug discovery
• - Most computational methods focus on binary classification of DT interactions
• - Protein-ligand interactions involve a continuum of binding strength values, known as binding affinity, which is challenging to predict accurately
• - Advanced learning techniques such as deep learning architectures can be used to predict binding affinities with the increase in available affinity data in DT knowledge-bases
• - This study proposes a deep-learning based model that uses only sequence information of both targets and drugs to predict DT interaction binding affinities
• - The proposed model uses 1D representations of targets and drugs with convolutional neural networks (CNNs)
• - The model achieved the best Concordance Index (CI) performance compared to two state-of-the-art methods: KronRLS algorithm and SimBoost, by constructing high-level representations of a drug and a target via CNNs.
• - This study presents a novel approach for predicting DT interaction binding affinities using deep learning architecture with only sequence information.

Summary: Scientists need to find new ways to make medicine. They use computers to help them. The computer tries to guess if a medicine will work with a certain part of the body. This is hard because sometimes it's not a perfect match. But now, they have a new way to guess better using special computer programs that learn from lots of examples. Definitions- Drug-target interactions: When medicine works with a certain part of the body. - Computational methods: Using computers to help solve problems. - Binary classification: Sorting things into two groups (yes or no). - Binding affinity: How well medicine and the body part fit together. - Deep learning architectures: Special computer programs that can learn from lots of examples and get better at guessing over time. - Convolutional neural networks (CNNs): A type of deep learning program that can understand patterns in information like pictures or sequences of letters/numbers. - Concordance Index (CI): A way to measure how good the computer program is at guessing if medicine will work with a certain part of the body.

Drug Discovery: Predicting Drug-Target Interaction Binding Affinities with Deep Learning

In the field of drug discovery, identifying new drug-target (DT) interactions is crucial. While many computational methods have been proposed to predict DT interactions, most focus on binary classification - determining whether a DT pair interacts or not. However, protein-ligand interactions involve a continuum of binding strength values, known as binding affinity, which remains a challenge to predict accurately. With the increase in available affinity data in DT knowledge-bases, advanced learning techniques such as deep learning architectures can be used to predict binding affinities.

Deep Learning Model for Prediction

This study proposes a deep-learning based model that uses only sequence information of both targets and drugs to predict DT interaction binding affinities. Unlike previous studies that use either 3D structures of protein-ligand complexes or 2D features of compounds for prediction, this work models protein sequences and compound 1D representations with convolutional neural networks (CNNs).

Performance Evaluation

The results show that the proposed deep learning-based model using 1D representations of targets and drugs is an effective approach for drug target binding affinity prediction. The authors also compare their model's performance against two state-of-the-art methods: KronRLS algorithm and SimBoost. In one larger benchmark dataset, their model achieved the best Concordance Index (CI) performance by constructing high-level representations of a drug and a target via CNNs. This outperformed both KronRLS algorithm and SimBoost.

Conclusion

Overall, this study presents a novel approach for predicting DT interaction binding affinities using deep learning architecture with only sequence information. The results demonstrate its effectiveness compared to other state-of-the art methods and highlight its potential application in drug discovery research.